ADAC technology platform - the next step in personalized immunotherapy

Precision therapy through affinity-based antibody conjugation

Recent News & Events

Strike Pharma presents updates at CICON24

Strike Pharma presents updates at CICON24

Strike Pharma granted patent to protect core technology

Strike Pharma has been granted a patent in Japan (JP 2021-529122), protecting the company’s core ADAC technology

Strike Pharma receives funding from BIO-X Accelerate program

The project is financed by the European Regional Development Fund (ERDF) through The Swedish Agency for Economic and Regional Growth via STUNS program BIO-X Accelerate

Strike Pharma presents further developments at CICON23

Scientists from Strike Pharma presented two scientific posters demonstrating progress in the preclinical development of STRIKE2001-KRAS and in the use of the ADAC technology platform for drug cargo delivery.

Strike Pharma and FyoniBio conclude successful cell line development of Strike’s bi-specific antibody and clinical lead candidate

FyoniBio to present data at PEGS Boston 2023

Strike Pharma presents latest developments at AACR 2023

Chief Scientific Officer, Associate Professor Sara Mangsbo, presented some of the latest data demonstrating progress in the development of the ADAC technology platform for precision cancer immunotherapy.

Funds awarded to study ADAC™ technology in depth

Research to be supported by Cancerfonden, one of Sweden’s largest financiers of cancer research

Strike Pharma continues expansion of management team

Joacim Elmén appointed as Director, CMC

Strike Pharma and FyoniBio sign Master Service Agreement

Agreement covers Cell Line Development for a novel bi-specific therapeutic mAb

Strike Pharma’s Chief Scientific Officer receives BiotechBuilders Award 2022

Dr. Sara Mangsbo acknowledged for entrepreneurship and her contribution to Swedish life science industry

Strike Pharma strengthens Board of Directors

Niclas Stiernholm elected as Chairman of the Board